FAQs

The TRP Supply Chain & Manufacturing Summit is the only industry conference exclusively dedicated to the supply chain, manufacturing, and CMC challenges of targeted radiopharmaceuticals (TRPs) and radioligand therapies (RLTs).

Now in its 4th year, the summit brings together 60+ senior leaders from big pharma, biotech, CDMOs, isotope providers, and logistics specialists who are responsible for delivering radiopharmaceutical drug products from bench to patients, reliably, safely, and at scale.

Taking place in in September 2026, this intimate, expert-led forum provides a focused environment to tackle the most pressing operational, regulatory, and technical bottlenecks in radiopharmaceutical supply chains today,  from isotope production and GMP manufacturing through cold-chain logistics to last-mile patient delivery.

The radiopharmaceutical field has seen unprecedented momentum since the FDA approval of Pluvicto (177Lu-PSMA-617) in 2022, triggering multi-billion dollar acquisitions from BMS, Eli Lilly, Sanofi, AstraZeneca, and Bayer. Clinical trials for alpha and beta isotope therapies are advancing to Phase 2 and Phase 3 — but the supply chain and manufacturing infrastructure is struggling to keep pace.

In 2026, several converging pressures are forcing supply chain, CMC, and manufacturing leaders to act:

• A global scramble to secure isotope supply — particularly for emerging alpha emitters such as actinium-225, astatine-211, lead-212, and terbium — as clinical demand outstrips production capacity
• Increasing pressure on just-in-time manufacturing and cold-chain logistics as more short-half-life radiopharmaceuticals enter late-stage trials
• New FDA draft guidance on maximum allowable dose, microdosing for alpha emitters, and radiopharmaceutical facility inspection standards
• A major wave of capital investment in new manufacturing sites, with Novartis, TerraPower, AtomVie, and others committing hundreds of millions to expand radiopharmaceutical production capacity across the US
• Growing demand for CDMO partnerships, automated synthesis platforms, and scalable GMP manufacturing as smaller biotechs accelerate their radioligand therapy pipelines

The 4th TRP Supply Chain & Manufacturing Summit is the industry's essential forum for addressing these challenges head-on.

This summit is designed for senior professionals who are responsible for the operational delivery of radiopharmaceutical programs; from the point of isotope production through to patient dosing. Attendees typically include:

• Vice Presidents, Directors & Heads of Supply Chain — Radioligand Therapy, Radiopharmaceuticals, RLT
• Heads of CMC, Process Development & Technology Transfer — Radiopharmaceuticals
• Directors of Manufacturing & GMP Operations — Radiopharmaceutical Drug Products
• Quality Assurance & Quality Control Leaders — Radiopharmaceutical Manufacturing
• Isotope Production & Supply Chain Specialists
• Analytical Development & Radiochemistry Leaders
• Logistics & Cold-Chain Operations Managers — Radioactive Materials
• Chief Operating Officers & Chief Technology Officers — Radiopharma Biotechs
• CDMO Business Development & Technical Operations Leaders
• Nuclear Medicine Scientists & Radiopharmacists — Academic & Clinical Institutions

This is not a clinical efficacy meeting. Attendees come specifically to solve operational, manufacturing, and supply chain problems — making it one of the most targeted and commercially valuable networking environments in the radiopharma calendar.

The summit attracts professionals from the full radiopharmaceutical ecosystem — big pharma, specialist radiopharma biotechs, CDMOs, isotope providers, logistics specialists, equipment manufacturers, and construction & facility design companies.

Previous attendees and speakers have included teams from: SpectronRx, NorthStar, Nucleus Radiopharma, OranoMed, Evergreen Theragnostics, Alpha-9 Oncology, Mariana Oncology, Lantheus, Novartis, AstraZeneca, Radiopharm Theranostics, Ratio Therapeutics, Abdera Therapeutics, Clarity Pharrmaceuticals, Andarix Pharmaceuticals, Alliance Medical & more.

The summit runs across three days:

• Pre-Conference Workshop Day, Two expert-led, three-hour workshops running in parallel, limited to small groups for in-depth, interactive discussion. Workshop topics are designed to deep on specific operational challenges.
• Conference Day 1 & Day 2, A single-track programme of, case study presentations with audience discussion, panel debates, follow-up roundtables, and facilitated mastermind sessions. Structured networking runs throughout both days.

The single-track format is intentional. With 60+ senior professionals in the room, the most valuable output is the conversation, between sessions, across breaks, and in the roundtables. The programme is designed to generate those conversations, not just broadcast at the audience.

There is no other industry conference with 100% of its content dedicated to radiopharmaceutical supply chain and manufacturing. This is the key differentiator:

• Laser focus: no clinical efficacy data, no target selection sessions, no preclinical biology. Every session addresses the operational, manufacturing, regulatory, or logistics challenges of delivering radiopharmaceutical therapies to patients.
• Intimate format: 60–70 attendees means you will be able to meet everyone in the room. Conversations are candid, networking is efficient, and the signal-to-noise ratio is exceptionally high.
• The right seniority: the audience is made up of the people making supply chain and manufacturing decisions, not students, clinicians, or observers.
• Cross-ecosystem: big pharma supply chain leaders, radiopharma biotech CMC teams, CDMOs, isotope providers, and logistics specialists are all in the same room, enabling the cross-supply-chain conversations that don't happen at larger, siloed events.

Compared with the broader TRP US Summit and TRP Europe Summit, which cover the full drug development lifecycle across multiple tracks, the TRP Supply Chain & Manufacturing Summit offers unmatched depth and peer specificity for operational leaders.

The TRP series includes four distinct meetings, each serving a different purpose within the radiopharmaceutical drug development ecosystem. The TRP US Summit and TRP Europe Summit are end-to-end meetings covering the full development lifecycle, from target selection and preclinical biology through to manufacturing and commercialisation, across multiple tracks and a broader audience.

The TRP Supply Chain & Manufacturing Summit is different in one fundamental way: 100% of the content is dedicated to supply chain, manufacturing, CMC, quality, and logistics. There are no sessions on target biology, preclinical efficacy, or clinical outcomes. If your job is to get the drug made and delivered, not designed, this is the meeting built for you.

The Workshop Day runs the day before the main conference and offers two three-hour deep-dive sessions running in parallel. Workshops are limited to small groups and are designed for experts who want to move beyond awareness into structured problem-solving with peers.

2026 workshops will explore:

• Intersection of geopolitical reality and operational supply chain strategy, specifically for radiopharmaceutical programmes where the product is decaying in transit and there is no margin for error.
• The number one challenge cited by every single company developing a radiopharmaceutical program: Isotope Supply, and the technologies and supply pathways that will shape availability over the next 5-10 years.

Workshop topics are intentionally specific and expert-led.  They have been designed for supply chain, manufacturing, CMC, and quality professionals who are actively working on these challenges, not those exploring radiopharma for the first time.

The Workshop Day is available as a full package alongside the main conference, or as a standalone addition. Delegates who register for the full package benefit from a significantly richer programme and deeper peer networking. Workshop uptake is capped to preserve the quality of the small-group discussion format.

Networking is central to the value of this summit, the intimate format means every delegate is accessible, and the shared operational focus creates an immediate common language.

Dedicated networking opportunities include:

• Speed networking at the opening of Day 1, structured introductions across the full delegate group
• Extended morning and afternoon breaks with refreshments in the exhibition space
• Facilitated roundtables and mastermind sessions, small-group peer exchange on live challenges
• Two full conference lunches and a workshop day lunch with open seating

The exhibition space brings together CDMOs, isotope providers, equipment manufacturers, logistics specialists, and construction & facility design companies, enabling the cross-supply-chain conversations that directly support both primary attendees and their vendor partners.

Both, and that cross-stage perspective is part of what makes the programme valuable. The supply chain and manufacturing challenges in radiopharmaceuticals span the entire development timeline, and the decisions made in Phase 1 often determine whether a program can scale to Phase 3 and beyond.

That said, the 2026 programme places particular emphasis on the Phase 2 to Phase 3 inflection point, the moment when patient cohorts grow significantly, isotope demand increases sharply, and manufacturing processes need to be locked down for regulatory submission. This is where supply chain fragility tends to become visible, and where the most urgent conversations in the field are happening right now.

Attendees include professionals working across preclinical supply, Phase 1 and 2 clinical manufacturing, Phase 3 scale-up, and commercial operations, giving the room a rare breadth of perspective that benefits everyone present.

Yes, the CDMO relationship is one of the central commercial and operational dynamics in the radiopharmaceutical supply chain, and it will feature prominently throughout the programme. For smaller biotechs without in-house manufacturing capability, CDMOs are the only route to clinical supply. For larger pharma companies, the question of when to outsource versus build in-house, and how to manage the transition, is a live strategic decision.

The programme will address how to evaluate and select a CDMO for radiopharmaceutical manufacturing, how to structure tech transfer and process control agreements, how to align quality systems and documentation requirements between sponsor and CDMO, and how to manage the relationship as programs scale. The CDMO perspective will also be represented directly through speakers and sponsors in the exhibition space, giving delegates access to candid conversations with providers about their capabilities and constraints.

The summit is designed for practitioners who are actively working on radiopharmaceutical supply chain and manufacturing, not for those exploring the field for the first time. The programme assumes familiarity with GMP manufacturing, isotope supply dynamics, and the basic operational vocabulary of drug development. Sessions are pitched at senior professionals making real decisions in real programs.

That said, if your organisation has recently entered the radiopharmaceutical space, through acquisition, partnership, or internal pipeline expansion, and you have professionals now responsible for building supply chain and manufacturing capability, this meeting is exactly the right place to accelerate their understanding. The peer networking alone, with 60+ specialists in the room, is among the fastest ways to compress years of learning into two days.

The 4th TRP Supply Chain & Manufacturing Summit takes place in Boston, MA. Boston is the natural home for this meeting: it is the epicentre of the US radiopharmaceutical and broader oncology biotech ecosystem, with a high concentration of the pharma and biotech companies, academic institutions, and specialist service providers who make up the summit's audience. Holding the event in Boston minimises travel friction for the majority of North American attendees while remaining accessible for the significant contingent of European delegates who attend each year.

Delegate registration is open to professionals working within biopharma, biotech, and academic institutions on the research, development, manufacturing, supply chain, CMC, quality, or regulatory aspects of radiopharmaceutical drug products.

Group discounts are available when you attend with colleagues. Please contact the registration team for current group pricing options. Early-bird rates are also available for a limited period at launch, registering early is strongly recommended given the capped capacity of this intimate summit.

For registration enquiries and speaking opportunities, please contact: info@hansonwade.com

For sponsorship and exhibition enquiries, please contact: sponsor@hansonwade.com